IL1A and idiopathic pulmonary fibrosis: Moreover, the administration of a caspase-8 inhibitor, z-IETD-fmk (IE, 0.5 μg/ml) did not alter IL-1α levels when IPF-derived PBMCs were treated with LPS ± ATP (Figure 2E).